Review article: systemic treatment of hepatocellular carcinoma.

ABSTRACT:

Background

The approval of the tyrosine kinase inhibitor sorafenib in 2007 marked a milestone in the treatment of hepatocellular carcinoma, as sorafenib was the first systemic therapy to show a survival benefit in patients with advanced hepatocellular carcinoma. Since then many drugs failed in the first- and second-line setting and it took almost another decade until further tyrosine kinase inhibitors succeeded in phase III trials.

Aim

To summarise the evolving field of systemic therapy of hepatocellular carcinoma.

Methods

We reviewed recently published studies identified from PubMed and data presented at recent meetings. Main search terms included hepatocellular carcinoma, tyrosine kinase inhibitors, immunotherapy, immune checkpoint inhibitors, sorafenib, regorafenib

SUBMITTER: Pinter M 

PROVIDER: S-EPMC6120553 | biostudies-literature | 2018 Sep

REPOSITORIES: biostudies-literature